The role of poly adenosine diphosphate–ribose polymerase (PARP) inhibitors in ABC with germline BRCA PV/LPVs is well established, and two PARP inhibitors (PARPi), olaparib and talazoparib, are currently approved for the treatment of metastatic gBRCA1/2m HER2− BC, irrespective of HR expression [9,10]. This evidence concerns the gene HR and breast cancer.